Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $149.23 which represents a decrease of $-0.37 or -0.25% from the prior close of $149.6. The stock opened at $149.93 and touched a low of ...

Kaustubh Bagalkote GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in ...

Johnson & Johnson (JNJ) closed the most recent trading day at $149.23, moving -0.25% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.3%. At the same time ...

Key Insights Given the large stake in the stock by institutions, Johnson & Johnson's stock price might be vulnerable ...

With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $176.92, representing a 20.98% upside. In a report released on December 11, Citi also maintained ...

Shares of Johnson & Johnson JNJ slid 0.27% to $146.24 Thursday, on what proved to be an all-around rough trading session for ...

This was the stock's second consecutive day of losses.

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.36 which represents a decrease of $-2.44 or -1.58% from the prior close of $154.8. The stock opened at $154.8 and touched a low of ...

Johnson & Johnson an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of JNJ ...

Notably, the $205 average of analysts’ price estimate for ABBV, reflects over 20% upside from its current levels of around $165. While ABBV stock may outperform JNJ stock in the next three years ...